Description
N-Acetyl Selank Amidate is a chemically modified variant of the classical Russian anxiolytic peptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro). The N-terminal acetylation and C-terminal amidation protect the molecule from enzymatic degradation and substantially extend biological half-life.
Per study reports the substance acts like parent compound Selank: modulation of GABAergic and serotonergic pathways with anxiolytic action without typical benzodiazepine side effects like sedation or dependence. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia for treatment of anxiety disorders.
The acetylated and amidated variant theoretically brings better pharmacokinetics at the same action mechanism. Direct comparison studies between NA-Selank and Selank are however limited.
Selank itself is used as nasal drops in Russia, so the nasal route is the one on which the peptide was studied clinically. There are no human data on the NA amidate form itself.
This variant is a ready-to-use nasal spray: 10mg or 30mg of N-Acetyl Selank Amidate dissolved in 5 ml saline and 0.4 ml bacteriostatic water (5.4 ml in total), nothing to mix yourself. One spray (0.1 ml) delivers about 185 mcg, or about 556 mcg in the 30mg variant. A bottle lasts for about 50 sprays. It is made fresh once you place your order and ships as an express item. As a powder for reconstitution, N-Acetyl Selank Amidate remains available in vials.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
N-Acetyl Selank Amidate is considered very well tolerated per study reports. The safety profile follows the parent compound Selank, which is consistently described as low in side effects, without typical benzodiazepine drawbacks such as sedation or dependence.
Observed in research and user reports:
- Intranasal irritation: with intranasal use, mild burning, dryness or irritation of the nasal mucosa is the most common observation.
- Fatigue: occasional reports of brief fatigue or calming, as the compound addresses anxiolytic pathways.
- No data on the modified variant: direct comparison studies between NA-Selank and the original Selank are limited. Robust long-term human data on the acetylated and amidated form do not exist.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank - Doklady Biochemistry and Biophysics 2010, Kolomin et al: shows Selank modulates hippocampal gene expression after single and repeated dosing.
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission - Frontiers in Pharmacology 2016, Volkova et al: documents Selank-induced changes to GABAergic genes, supporting the anxiolytic pathway.
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells - Frontiers in Pharmacology 2017, Filatova et al: shows in a cell model that Selank shifts expression of GABAergic receptor components.
- Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo - Doklady Biological Sciences 2008, Inozemtseva et al: intranasal Selank raises BDNF mRNA and protein in the rat hippocampus.
- Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats - Bulletin of Experimental Biology and Medicine 2019, Kolik et al: shows protective effect against ethanol-induced memory impairment via BDNF.
